Stock BCYC BICYCLE THERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Bicycle Therapeutics plc

Equities

BCYC

US0887861088

Market Closed - Nasdaq
Other stock markets
 21:00:00 08/05/2024 BST 		5-day change 1st Jan Change
23.62 USD +2.34% Intraday chart for Bicycle Therapeutics plc -2.40% +30.64%
05-06 European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading MT
05-02 European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Bicycle Therapeutics : May 2024 Corporate Deck
PU
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
BU
Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
BU
Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
BU
Bicycle Therapeutics to Present at the AACR Annual Meeting 2024
BU
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
BU
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
BU
Bicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
BU
Bicycle Therapeutics : 2023 R&D Day Deck
PU
Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day
BU
IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
Bicycle Therapeutics to Host R&D Day on December 14
BU
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day
BU
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
BU
Bicycle Therapeutics Selected to Participate in FDA Program to Expedite Commercial Manufacturing Readiness of BT8009 for Metastatic Bladder Cancer
BU
Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director
AQ
Bicycle Therapeutics : BT8009 Regulatory Update | Bicycle Therapeutics
PU
Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer
BU
Bicycle Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
BU
Bicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BCYC Stock
  4. News Bicycle Therapeutics plc
  5. Press Releases